Gut bug may reveal who responds to prostate cancer drug
NCT ID NCT06242509
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether a specific gut bacterium, Akkermansia muciniphila, can predict how well men with advanced prostate cancer respond to a common hormone therapy (abiraterone acetate). Researchers will collect stool and blood samples from 52 men over three months to track changes in the bacteria and compare them to treatment response. The goal is to find a simple, non-invasive way to identify who will benefit most from this therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could lead to a simple stool test to predict which prostate cancer patients will benefit from certain hormone therapies.
What could go wrong
This is a small, early-stage observational study (52 participants) that only looks for a link, not a proven treatment. The findings may not apply to all patients or lead to a practical test.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hôpital Saint Louis AP-HP
RECRUITINGParis, France
Contact Phone: •••-•••-•••• Email: •••••@•••••